CEL-SCI Corporation (NYSE:CVM) issued a shareholder letter detailing progress on Multikine, a pre-surgical cancer therapy for head and neck cancer. The therapy showed significant survival benefits in a specific patient population, leading to regulatory filings for marketing clearance. CEL-SCI completed its manufacturing facility commissioning and is in discussions with major regulatory bodies including the FDA, EMA, MHRA, and Health Canada. The company plans to seek immediate patient access to Multikine through conditional approvals.